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Purpose: Dexibuprofen is an enantiomer of ibuprofen with low bioavailability which results 
from its hydrophobic nature. Nanosuspensions have developed a podium to solve the in vitro 
dissolution problem that frequently occurs in current research.
Materials and methods: The drug and polymer solutions were mixed in a microchannel 
fluid reactor and the successive embryonic nanosuspension was decanted into a vial having the 
polymer solution. The impact of different process and formulation parameters including inlet 
angle, antisolvent and solvent flow rate(s), mixing time, drug concentration, polymer type and 
concentration was evaluated.
Results and discussion: Stable dexibuprofen nanocrystals with a particle size of 45±3.0 nm 
and polydispersity index of 0.19±0.06 were obtained. Differential scanning calorimetry and 
powder X-ray diffraction confirmed the crystallinity. The key parameters observed were inlet 
angle 10°, antisolvent to solvent volume of 2.0/0.5 mL/min, 60 minutes mixing with 5 minutes 
sonication, Poloxamer-407 with a concentration of 0.5% w/v and drug concentration (5 mg/mm). 
The 60-day stability studies revealed that the nanocrystals were stable at 4°C and 25°C. The 
scanning electron microscopy and transmission electron microscopy images showed crystalline 
morphology with a homogeneous distribution.
Conclusion: Stable dexibuprofen nanocrystals with retentive distinctive characteristics and 
having marked dissolution rate compared to raw and marketed formulations were efficiently 
fabricated. In future perspectives, these nanocrystals could be converted to solid dosage form 
and the process can be industrialized by chemical engineering approach.
Keywords: nanocrystal, dexibuprofen, microchannel fluidic reactor, process and formulation 
parameters
Introduction
The issue of poor water solubility for a list of drug candidates has become a hard 
challenge for the drug delivery scientists both from academia and research and 
development sectors.1 As per the scientist reports, nearly 70% of the applicant drugs 
in development phase and 40% of marketed APIs available as oral dosage forms are 
practically insoluble in water.2 The issue of poor water solubility would lead to erratic 
bioavailability and, consequently, unwanted toxic effects.3 Drug delivery scientists, 
by their continuous struggle, have developed and designed a range of strategies to 
boost the solubility and dissolution of medicines in aqueous media, including solid 
dispersions, solubilization, emulsions, micronization and so on.4 However, these 
approaches have limited applications because of the production of ionizable groups, 
stability issues and limited improvement in solubility.5 In addition the added solvents 
residues, enhances the solubility that can lead to potential toxicity and other unwanted 
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side effects. It is, therefore, the utmost need to develop 
alternative approaches to enhance the solubility of plethora 
of drug compounds.6
It has become evident from the present literature that 
nanosuspensions have developed a podium to solve the 
in vitro dissolution problem that frequently occurs in 
current research.7 Nanocrystal can be created by bottom-up 
and top-down methods.8 In top-down methods, the size 
reduction occurs by mechanical forces and attrition forces. 
However, some of the issues associated with top-down 
methods include long processing time, broad particle size 
distribution and contamination.9 Bottom-up method involves 
antisolvent precipitation in which the significant footstep 
is nucleation.10 The issues associated with the bottom-up 
methods are uncontrolled particle growth through Ostwald 
ripening and changes in particle attributes with partial or 
complete conversion to amorphous state, which can poten-
tially cause phase transition and stability issues.9,11 It is of 
paramount importance for crystalline nanoparticles to be 
fabricated because it causes long-term stability.7
Dexibuprofen is the active form of ibuprofen in vitro and 
in vivo.12 It is rapid acting and used in a decreased quantity as 
compared to its racemic mixture.13 It is indicated for dental 
pain, dysmenorrhea, postoperative pain and headache.14 
It is a Biopharmaceutics Classification System class II 
drug. Its aqueous solubility is 51 µg/mL as compared to 
ibuprofen (21 µg/mL), and its bioavailability is low in the 
gastric environment, which can be enhanced by increasing 
its aqueous solubility.15
The basic principle of antisolvent precipitation with 
syringe pump (APSP) is the addition of drug molecules from 
organic phase through a syringe pump into aqueous polymer 
phase and, consequently, nucleation and particle formation 
occur while the microchannel fluidic reactor (MCFR) has 
a small channel in which the liquid behavior is in contrast 
to the conventional flow theory, that is, the liquids follow 
laminar flow pattern without turbulence and mixing of 
liquid occurs due to diffusion of molecules across the liquid 
interface.16 MCFR is a novel advanced low-energy bottom-up 
approach, which is different from APSP. Basically, in these 
approaches, the important step is micromixing of antisolvent 
aqueous polymer solution and organic solvent drug solution, 
which controls the nucleation, crystal size and attributes of 
the nanocrystal. In the APSP method, only the solvent drug 
solution is controlled, while in MCFR, both the solutions 
(antisolvent and solvent solutions) are controlled, leading to 
more control on nucleation, particle size, size distribution, 
stability and characteristics of the nanocrystals.
This study aimed to evaluate the modified MCFR process 
and produce nanocrystals of dexibuprofen through the 
modified MCFR method. The hydrocortisone nanoparticles 
reported by Ali et al17 were produced by MCFR with a 
particle size above 200 nm. In that method, the crystallized 
nanoparticles were mixed with the buffer solution composed 
of polymers using stirring and sonication. However, in this 
new method, we used a polymeric solution during mixing 
of the drug solution in MCFR as well as after processing the 
nanosuspension. Crystallization of the drug in plain water and 
in polymeric medium are substantially different from each 
other. In polymeric medium, the nucleation and particle size 
are controlled by the polymer molecules, which results in 
low particle size and homogenous size distribution.18 In the 
current project, the special characteristics of nanocrystals 
were investigated by executing different assessments which 
included the particle size, zeta potential, powder X-ray 
diffraction (PXRD), differential scanning calorimetry 
(DSC), scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), stability studies and in vitro 
dissolution.
Materials and methods
The following were the chemicals and the manufacturers 
from where they were obtained: dexibuprofen (batch no 
C102-150100M; Hubei Biocause Helen Pharmaceutical, 
Hubei, China), Poloxamer-407 (batch no BCBK50056; 
Sigma-Aldrich, Dorset, UK), polyvinylpyrrolidon-K30 
(batch no 08297052 G0; BASF, Ludwigshafen, Germany), 
hydroxypropyl methyl cellulose (HPMC) viscosity 15cps 
(batch no 8028213; Shin-etsu, Tokyo, Japan). Laboratory 
distilled water was obtained from the research laboratory of 
Bradford University.
Preparation of dexibuprofen 
nanosuspension
The current method is a modification of the previously pub-
lished method of Ali et al.17 Dexibuprofen dissolved in ethanol 
(5 mg/mL) and polymers dissolved in aqueous phase were 
introduced into MCFR (inlet angle 10° with internal diam-
eter of 0.5 mm) at a flow rate 0.5:2.0 mL/min, respectively. 
Then, the emergent nanosuspension was poured into a vial 
having aqueous polymer solution and stirred for 60 minutes 
(Figure 1). At the end, the nanosuspension was sonicated 
for 5 minutes with 100 W ultrasonication (P1200; Crest 
Ultrasonic, Ewing Township, NJ, USA).19 The impact of five 
important process parameters including 1) polymer type and 
its concentration, 2) inlet angle, 3) solvent and antisolvent 
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flow rates, 4) drug concentration and 5) stirring time with and 
without ultrasonication was assessed at three levels.
Particle size and zeta potential 
measurements
Particle size measurements of the produced nanosuspension 
were determined through photon correlation spectroscopy 
(Zetasizer® NanoS; Malvern Instruments, Malvern, UK). All 
the samples were subjected to particle size analysis without 
further dilution. The average particle size diameter (Z.Ave) 
and the polydispersity index (PDI) were determined from 
three measurements. Additionally, the zeta potential calcula-
tions of the produced nanoparticles were carried out using 
the Malvern Zetasizer. The clear disposable zeta cells were 
used for zeta potential measurements. The samples were 
analyzed in triplicate.
seM
The morphology of unprocessed dexibuprofen was evaluated 
using SEM (Quanta 400; FEI, Cambridge, UK). The images 
were taken at different magnifications levels. Gold coating 
of the dexibuprofen particles using sputter coater was carried 
out to obtain clear images.
TeM
The external morphology of the produced nanosuspension 
was characterized by TEM (JEM-1200EX; JEOL, Tokyo, 
Japan) performed at 100 kV. Nanosuspension drop was 
poured on copper grid surface and dried at ambient tempera-
ture; then, magnesium uranyl acetate solution was applied as 
a 2% aqueous solution for negative staining.
Dsc analysis
Thermal characteristics of the processed and unprocessed dexi-
buprofen were assessed using DSC (Discovery; TA Instrument, 
New Castle, DE, USA). The DSC instrument was calibrated 
with indium 99% and zinc having melting points 156.6°C and 
419.5°C, respectively. Under nitrogen atmosphere, the scan-
ning rate of 10°C/min was used for both raw and nanocrystals. 
The scan was performed at temperature ranging from 0°C to 
100°C. All the samples were analyzed in triplicate.
X-ray powder diffraction analysis
The X-ray powder diffraction of raw and produced nanocrys-
tals was carried out with D5000 diffractometer (Siemens, 
Munich, Germany) consuming Cu Ka radiation (X=1.5418 
A). The samples were measured with the angle range of 
5°–50°, step size of 0.05°, count time of 3 seconds per step, 
rotation during analysis 30 rpm and the generator fixed at 
40 kV and 30 mA.
stability studies
Dexibuprofen nanosuspensions were assessed for their chem-
ical stability at regular time intervals in 1 week (day 0, day 1, 
day 3, day 4, day 5, day 6, day 7) and the % of drug content 
3RO\PHUDTXHRXVVROXWLRQDQWLVROYHQW
3RO\PHUDTXHRXVVROXWLRQ
6WLUUHUPL[LQJ
1DQRFU\VWDO
0LFURFKDQQHOIOXLGLFUHDFWRU
'UXJVROXWLRQVROYHQW
Figure 1 schematic presentation of fabrication of dexibuprofen nanocrystal through McFr.
Abbreviation: MCFR, microchannel fluidic reactor.
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was evaluated with UV spectrophotometer (V-630; JASCO) 
at 222 nm as per the method reported previously.20 More-
over, physical stability study of the produced dexibuprofen 
nanosuspension was carried out at 25°C and 4°C for 60 days. 
The growth of the particles was monitored by measuring the 
particle size and PDI values at regular time intervals.
in vitro dissolution
The dissolution rate of the produced dexibuprofen nano-
crystals was compared with those of raw and marketed 
formulations. The dissolution study was carried out using 
USP XXIV rotating paddle method. The sample was placed 
in dissolution vessels containing 900 mL phosphate buffer, 
pH 7.2, maintained at 37°C±0.5°C with a stirring speed of 
100 rpm, which has been reported for nanosuspension.20,21 
The samples were collected after 5, 10, 15, 20, 25, 30, 40, 50, 
and 60 minutes through a filter (Millex®GP; IRL) with a pore 
size of 0.22 µm and were substituted with equal amount of 
fresh phosphate buffer solution. The samples were assessed 
on UV spectrophotometer (V-630; JASCO) at 222 nm.
statistical analysis
Statistical analysis of the experimentally collected data was 
done by SPSS 18 (SPSS Inc., Chicago, IL, USA). The data 
for all drugs were collected in triplicate. The data presented 
here are as mean ± SD. One-way analysis of variance test 
(P,0.05) and least significant difference test were used.
Results and discussion
impact of process conditions on the 
particle size of dexibuprofen nanoparticles
This is a low-energy method which can produce stable drug 
nanocrystals. However, process optimization is important 
to be taken under consideration. Interestingly, a variation 
in particle size of the dexibuprofen was observed while 
changing the parameters. The impact of three levels of these 
parameters on the particle size is described below.
evaluation of polymers
The effect of polymer type and concentration on the particle 
size of dexibuprofen nanocrystals was assessed (Figure 2). 
Poloxamer-407, PVP-K30 and HPMC-15cps were tested 
in single and combination forms at various concentrations. 
Poloxamer-407 (0.5% w/v) was found to be the most suitable 
polymer, and the nanocrystal attained a size of 45±3.0 nm 
with PDI of 0.19±0.06. Particle size distribution is presented 
in Figure 3.
Effect of flow rate of antisolvent 
and solvent
antisolvent volume variable and solvent volume 
constant
Antisolvent and solvent flow rate was assessed and it was 
observed that it had a dominant effect on nanocrystal size. The 
nanocrystal of smaller sizes was obtained while changing the 
antisolvent volume and keeping the drug solution constant. 
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Figure 2 effect of polymer type and its concentration on dexibuprofen nanocrystals.
Abbreviations: hPMc-15cps, hydroxypropyl methyl cellulose 15cps; PDi, polydispersity index; Polox-407, Poloxamer-407; PVP-K30, polyvinyl pyrrolidone k30.
Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2621
Fabrication and characterization of dexibuprofen nanocrystals
The nanoparticle size achieved at 2.0/0.5 mL/min was 45±3.0 
nm with a PDI of 0.19±0.06 (Table 1). The relatively smaller 
particle sizes obtained are attributed to two reasons. The first 
one is the perfect mixing of the drug solution with the anti-
solvent solution because the antisolvent solution volume is 
high compared to the drug solution.22 The second one is the 
higher supersaturation level achieved in beginning due to less 
drug solution and antisolvent concentration, which decreases 
the solute concentration on the nuclei surfaces.23
antisolvent volume constant and solvent volume 
variable
It was observed that keeping the antisolvent solution constant 
and increasing the volume of drug solution result in larger 
particles. The maximum size obtained at 2.0/2.0 mL/min 
was 803±3.0 nm with a PDI of 0.57±0.19 (Table 1). This 
effect is attributed to increase in drug concentration which 
inflates the solute fixation on the surface of framed nuclei 
and, thus, encourages molecular growth and produces 
bigger crystals.23
equal volume of antisolvent and solvent
At equal ratios of both solutions, it was observed that higher 
stream rate (2.0/2.0 mL/min) resulted in larger particle 
sizes (803±3.0 nm with a PDI of 0.57±0.19; Table 1). The 
higher particle sizes obtained at higher stream rate of both 
solutions are due to inadequate blending of the drug solu-
tion with the antisolvent solution as the dwelling time in 
MCFR is very short; so, inadequate diffusion takes place24 
and it may produce a non-uniform region supersaturation, 
subsequently producing bigger particles with more extensive 
size dispersion.17
Drug concentration effect
The drug concentration effect was evaluated and it was 
observed that larger particles sizes were obtained at higher 
concentrations (Table 1). Principally, higher concentration 
crops the growth of crystal through condensation and coagu-
lation phenomenon. Moreover, at higher concentrations, 
the viscosity of the drug solution is high, which decreases 
mutual diffusion of antisolvent and solvent solutions with 
consequent creation of non-uniform supersaturation that 
ultimately produces larger particles through agglomeration 
or crystal growth.25 Furthermore, BaSO
4
 and predniso-
lone nanoparticles in MCFR have been produced with the 
same effect.17,22
inlet angle of McFr
Three different inlet angles were investigated for their effect 
on particle size of the dexibuprofen nanoparticles. The nano-
particles produced by angle 50° were little a bit larger with 
slightly broader distribution as compared to those at angles 
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Figure 3 Particle size distribution of dexibuprofen nanoparticle (Poloxamer-407 [0.5%]).
Table 1 impact of process conditions on dexibuprofen 
nanoparticle size (n=3)
Input variable Output variable
Antisolvent 
flow rate 
(mL/min)
Solvent 
flow rate 
(mL/min)
Drug 
concentration 
(mg/mL)
Inlet 
angle
Avg P 
size±SD 
(nm)
PDI±SD
0.5 0.5 5 10 267±3.0 0.36±0.17
1.0 0.5 5 10° 192±4.0 0.34±0.09
1.5 0.5 5 10° 107±4.0 0.28±0.10
2.0 0.5 5 10° 45±3.0 0.19±0.06
2.0 1.0 5 10° 218±4.0 0.34±0.14
2.0 1.5 5 10° 397±4.0 0.39±0.17
2.0 2.0 5 10° 803±3.0 0.57±0.19
0.5 0.5 5 10° 267±3.0 0.36±0.17
1.0 1.0 5 10° 404±2.0 0.39±0.18
1.5 1.5 5 10° 573±4.0 0.43±0.22
2.0 2.0 5 10° 803±3.0 0.57±0.19
2.0 0.5 10 10° 336±5.0 0.37±0.07
2.0 0.5 15 10° 920±4.0 0.39±0.08
2.0 0.5 5 25° 62±3.0 0.22±0.09
2.0 0.5 5 50° 86±5.0 0.34±0.10
Abbreviation: PDi, polydispersity index.
Drug Design, Development and Therapy 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2622
Khan et al
10° and 25° (Table 1). It is thought that Keener delta edges 
(10° and 25°) have sharper channel edges which permit the 
two liquid streams to meet and then stream down the outlet 
without creating any interruption to either liquid stream,26 
while at an angle of 50°, the liquid streams encounter a more 
even level creating further disturbance of the meeting liquid 
streams while forwarding to the vent.
effect of mixing time
The effect of mixing time on nanosuspension was evalu-
ated and it was observed that 60 minutes mixing produced 
nanoparticles with smaller sizes as compared to 30 minutes 
mixing (Figure 4). Following mixing, the produced nano-
suspensions were sonicated with 100 W ultrasonication 
(P1200) for 5 minutes, which further reduced the size and 
PDI. Principally, high stirring rate and efficient mixing can 
potentially produce high level of micromixing, supersatura-
tion and rapid nucleation, and consequently, nanocrystals 
with relative smaller particle size are produced.27
stability studies
Stability of the nanocrystal is very significant because nan-
onization enhances surface area with increase in surface 
free energy, and consequently, stability of nanoparticle is 
greatly affected. Moreover, little bit of high solubility of 
the drugs at higher temperature leads to lower supersatura-
tion level with subsequent growth of nanoparticles through 
Ostwald ripening.28 The van der Waals forces among the 
nanocrystals lead to agglomeration and, consequentially, 
weaken the nanosuspensions. The zeta potential value 
obtained was -22.1±2.2 mV, and the literature reported 
value for nanosuspensions is ±20 mV.29,30 The chemical 
stability of the produced nanosuspensions was evaluated 
for 1 week as per the method reported previously.20 The 
% of the drug content of dexibuprofen nanosuspension 
stored for 7 days was 96.9%±2.6%. No sign of degrada-
tion was observed. Moreover, the produced nanosuspen-
sions were assessed for their physical stability at 4°C and 
25°C for a period of 60 days. It was observed that the 
nanosuspensions stored at both temperatures were stable 
and no significant growth occurred (Figures 5 and 6). The 
2-month stability data indicate homogenous distribution 
of nanoparticles and as per Deng et al,34 homogenous dis-
tribution prevents Ostwald ripening. Moreover, regarding 
nanosuspension stability, Freitas and Müller recommended 
that it should be kept in fridge (2°C–8°C) to retain its 
particle size.31
Thermal and X-ray analysis
The crystallinity of the nanocrystals was assessed and 
compared with that of the raw counterparts using DSC 
and PXRD. These studies confirmed that the nanoparticles 
were crystalline in nature. The raw drug and the produced 
nanoparticles had sharp melting endotherm. A reduction 
in melting point of nanocrystals was observed related to 
the raw drugs. The melting point of raw dexibuprofen was 
53.0°C, while that of dexibuprofen nanocrystal was 50.0°C 
(Figure 7). This is because of the small particle size and 
lower packing density of the nanocrystals lattice compared 
to those of raw particles.32 Basically, peak intensity shifted 
to lower level because of minor angle reflection by the 
nanocrystals. Furthermore, due to sizing effects, the peak 
for the nanocrystals was also found to be little broadened 
compared to the raw drug. The PXRD study also confirmed 
the crystalline characteristics of the nanoparticles. The PXRD 
diffractograms of the raw dexibuprofen was found to have 
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Figure 4 effect of mixing time on dexibuprofen nanoparticle size.
Abbreviation: PDi, polydispersity index.
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Abbreviation: PDi, polydispersity index.
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Figure 6 stability studies of dexibuprofen nanoparticle at .25°c.
Abbreviation: PDi, polydispersity index.
sharp and high-intensity peaks (Figure 8). On the other hand, 
disappearance of some peaks and decrease in the intensity of 
the peaks as well were observed for nanocrystals. Owing to 
small particle size effect, the diffraction patterns are different 
compared to those of raw drug, as the peak intensity has been 
shifted to a lower level due to minor angle reflection by the 
nanocrystal.33
Morphological studies
SEM and TEM were used to study the morphology of raw 
and processed dexibuprofen. The SEM images (Figure 9A) 
showed that the raw drug was crystalline and triangular and 
irregular in shape. In addition, the images of nanocrystals 
obtained by TEM (Figure 9B) clearly showed that the 
nanoparticles had a homogenous size distribution with size 
50 nm and also confirmed the crystalline nature.
in vitro dissolution
Investigation on the in vitro dissolution of the nanocrystals 
confirmed enhanced dissolution rate correlated to the raw 
and marketed tablets of dexibuprofen, that is, 200 mg. 
Figure 10 shows that ~85.4% of nanocrystals were dissolved 
in the first 5 minutes. On the other hand, raw dexibupro-
fen showed a dissolution rate of around 25.4% in the first 
5 minutes, while marketed tablets showed around 35.6%. 
This significant increase in dissolution rate of dexibu-
profen nanocrystals indicated that controlled nucleation 
produced nanocrystals with increased surface area and, 
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consequently, enhanced the dissolution rate.18 Moreover, it 
is already proved that as per the Ostwald–Freundlich equa-
tion, nanoparticles with a size below 100 nm have quicker 
dissolution rate.28
Conclusion
This study demonstrated that MCFR is a low-energy novel 
bottom-up technology which can potentially produce stable 
nanocrystals. However, the experimental and process condi-
tions need to be properly controlled. The optimized process 
conditions including solvent, antisolvent flow rates, inlet 
angles, stirring rate and mixing time are the key factors that 
alter the particle size of the nanoparticles. High antisolvent 
flow rate, small inlet angle, high mixing time and stirring 
rate are the favorable factors to produce nanocrystals with 
a small particle size. Additionally, the appropriate selection 
of the polymers/surfactant and the low concentration of 
the drug are the key factors to control the particle size dur-
ing nucleation. MCFR is a technology which produces the 
nanocrystals without changes in particle attributes, especially 
crystallinity of the particles. In future perspectives, this 
technology can potentially be scaled up. Also, the produced 
nanocrystals could be converted to the solid dosage form and 
Figure 9 (A) seM image of raw dexibuprofen and (B) TeM image of dexibuprofen 
nanoparticle.
Abbreviations: seM, scanning electron microscopy; TeM, transmission electron 
microscopy.
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Figure 8 X-ray diffractograms of nanoparticles of dexibuprofen and their raw 
counterparts.
0 10 20 30
2θ
40 50 60
Dexibuprofen unprocessed Dexibuprofen nanoparticle
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Figure 7 Dsc analysis of nanoparticles of dexibuprofen and their raw counterparts.
Abbreviation: Dsc, differential scanning calorimetry.
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the process industrialized at a large scale by using chemical 
engineering approach.
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